Project Information

• Status: 15 molecules were patented, a paper was published, and the molecules were licensed to BioNanoSim.

A sub-project of the CNS GPCRS focused on Peripheral CB1 receptor antagonists as anti-obesity drug candidates. Anti-targets are any central activity, CB1R agonism, other GPCR agonism, or antagonism, while CB2 agonism is promising.
Collaborating with Prof. Yossi Tam.
doi: https://doi.org/10.1021/acs.jcim.9b00577

Multitargeting Obesity

We are looking for targets associated with control of weight. Dr. Yuval Tabach found such 40 genes co-evolved along the evolution with CNR1 (the CB1R gene). We examined all 40 and found about 6-7 that have enough ligand data to enable modeling. We screened 18 million molecules and picked the top ~9500 which passed CB1R antagonism model, screened those through each and every other of the candidate receptors to find ~120 such candidates for multitargeting. Currently purchased 13 and 3 out of them are indeed multitarget for CB1R + another receptor.
Status: supported by Integra Holdings for 1 year, which is now over.